What is Gryphus Diagnostics?
Founded in 1998 and headquartered in Birmingham, Alabama, Gryphus Diagnostics has carved out a specialized niche in the development and manufacture of rapid detection systems. The company is particularly recognized for its proprietary sialidase technology platform, which has been instrumental in its growth within the women's health sector. Operating under rigorous ISO 9001:2000 and ISO 13485:1996 standards, Gryphus maintains a cGMP-certified manufacturing facility that ensures compliance with stringent FDA guidelines. Its product portfolio, which serves point-of-care facilities, hospitals, and clinical laboratories, is supported by a robust network of international distributors and licensees, cementing its status as a key player in the global diagnostics market.
How much funding has Gryphus Diagnostics raised?
Gryphus Diagnostics has raised a total of $84K across 1 funding round:
Debt
$84K
Debt (2021): $84K with participation from PPP
Key Investors in Gryphus Diagnostics
PPP
Public-Private Partnership
What's next for Gryphus Diagnostics?
With the recent influx of capital, Gryphus Diagnostics is poised to transition into a more aggressive growth phase. The strategic focus will likely center on scaling the production of its investigational product pipeline and enhancing its market penetration in key international territories. By optimizing its state-of-the-art laboratory environment and continuing its focus on quality-driven innovation, the company aims to solidify its leadership in the medical device industry. Future milestones will likely involve the commercialization of new diagnostic technologies that address unmet needs in women's health, further leveraging the company's established regulatory expertise and global supply chain infrastructure to drive long-term value for stakeholders.
See full Gryphus Diagnostics company page
